Vessel Closure


Haemostasis Management Solutions

Abbott is committed to providing haemostasis management solutions to help patients and hospitals thrive.

Our haemostasis management portfolio aims to drive hospital efficiency through:1-5

  • Early ambulation      
  • Optimising nursing time
  • Reducing patient length of stay
  • Driving overall hospital efficiency
  • Improving patient flow
  • Lowering complications
  • Improving patient outcomes

Vascular Closure Systems

PercloseTM Family: PercloseTM ProStyleTM and Perclose ProGlideTM

Don't Just Close it. PercloseTM it. 

PercloseTM ProStyleTM

PercloseTM ProGlideTM


PercloseTM family of products deliver a non-masking percutaneous suture to the access site that promotes primary healing†6 and has no re-access restrictions.7, 8


Broadest Indication

Perclose™ family of products – ProStyle™ and ProGlide™, have the broadest indication for both femoral arterial and venous access.*


For Common Femoral Access Sites


For arterial sheath sizes greater than 8F, at least two devices and the pre-close technique are required. 
For venous sheath sizes greater than 8F, at least one device and the pre-close technique are required. 

#Max. OD 26F/0.340 inches/8.62 mm; Max. OD 29F/0.378 inches/9.59 mm. Tests performed by and data on file at Abbott.9
Primary intention healing occurs where vessel wall edges are brought together, adjacent to each other. This can be achieved with sutures and other methods.6
*As compared to Angio-Seal‡, ExoSeal‡, FemoSeal‡, InClosure‡, MANTA‡, Mynx‡, PerQseal‡, Vascade‡, Velox CD‡, X-Seal‡. Data on file at Abbott.


Abbott's PercloseTM family of closure devices are designed to: 

  • Reduce time to haemostasis, ambulation and discharge10
  • Challenge and confirm closure complete haemostasis on the table7, 8
  • Maintain wire access7, 8
  • Minimise inflammatory response11
  • Reduce transfusions, infections, mortality and shorter length of stay compared to surgical cutdown for large-bore arterial access12
  • Leave minimal intravascular footprint
  • Reduce major access site-related complications for large-bore venous access4

With a legacy of more than 12 million repairs over 27 years, Perclose ProGlideTM  has been helping clinicians achieve rapid and durable haemostatis** with the certainty of percutaneous suture-mediated repair.4

**In the REALISM clinical trial Perclose™ cohort (n = 159), mean time to achieve haemostasis was 5.92 ± 6.19 minutes and freedom from major femoral vein access-related complications through 30 days was 98.1%.4

Product Features

Perclose™ ProStyle™ Suture-Mediated Closure and Repair (SMCR) System is the next-generation design evolution of the proven and trusted Perclose ProGlide™ SMC System.

Perclose™ ProStyle™ Device

Perclose™ ProStyle™ Device

Suture Trimmer

Shared Knot Pusher

Improvements made to Perclose™ ProStyle™ SMCR System

PercloseTM Deployment

Guide to Perclose™ ProStyle™ deployment

View the animations for System Overview, Device Preparation, and full deployment steps for Single Device Deployment and Multiple Device Deployment techniques.

System Overview


Single Device Deployment
Multiple Device Deployment

Note the key difference in suture management from ProGlide™ SMC system is the additional step involving the snared knot pusher.8



Guide to Perclose ProGlide™ deployment

View the animations for full deployment steps for single and multiple devices.


Single Device Deployment
Multiple Device Deployment

Clinical Trials

PEVAR Clinical Trial13

To compare the safety and effectiveness of the 'pre-close' technique for percutaneous femoral artery (FA) access and closure (PEVAR) to Surgical Cutdown (SEVAR).

Key findings: 
  • Mean procedure time was reduced in PEVAR patients by 34 minutes (106.5 ± 44.9 minutes PEVAR vs. 141.1 ± 73.4 minutes SEVAR, p**=.0056)13
  • Mean time to haemostasis was reduced following PEVAR by 13 minutes (9.8 ± 17.0 minutes PEVAR vs. 22.7 ± 22.9 minutes SEVAR, p=.0023)13
  • Prospective randomised 
  • 2:1 PEVAR: SEVAR
  • Perclose N = 50*, SEVAR N = 50
  • Multi-centre (20 U.S)
  • Non-inferiority


Primary Endpoint Achieved: 

Major Ipsilateral Vascular Access
Complications at 30 Days

Composite of Minor Ipsilateral Vascular Access
Complications at 30 Days

Major Complications: access site vascular injury requiring repair; new onset lower extremity ischaemia requiring surgical or percutaneous intervention; Access site-related bleeding requiring transfusion; access site-related infection requiring IV antibiotic or prolonged hospitalisation; access site-related nerve injury that is permanent or requires surgery.
‡Minor Complications: pseudoaneurysm or AV fistula; hematoma ≥ 6 cm; post-discharge bleeding requiring > 30 minutes to re-achieve hemostasis; lower extremity arterial emboli or stenosis attributed to access site; deep vein thrombosis; access site-related vascular laceration; transient access site-related nerve injury; access site wound dehiscence; access site-related lymphocele; localized access site infection treated with IM or PO antibiotic.
*PEVAR-Perclose analysed independently from ProstarTM XL.
**One-sided p-value and 95% confidence interval for non-inferiority test by using asymptotic test statistics with non-inferiority margin of 10%.


Clinical Evidence on Closure of Large-Bore Venous Access 

REALISM Clinical Trial - Perclose Cohort4

To evaluate the safety and effectiveness of Perclose™ ProGlide™ in closing large-sized venous access sites through a retrospective data collection.

Key Findings

  • Major complication** was low at 1.9%
  • Freedom from major femoral vein access site-related complications was 98.1% at 30 days
  • Perclose is safe and effective in the closure of venous access-site with up to 24F sheath
**Major complication is defined as any event leading to death, life-threatening or major bleeding, surgical intervention, hospitalisation, visceral ischemia or neurological impairment.7
Low major complications at 30 days



Real-World Evidence on Repair of Large-Bore Arterial Access

Perclose vs. Surgical Cutdown12

Compare clinical outcomes and complication rates among patients undergoing closure of large-bore arterial access using Perclose™ (Perclose) versus Surgical Cutdown (Cutdown) in a real-world setting.

Patient baseline: 



Key findings:

The use of Perclose for repair of large-bore arterial access is associated with significantly lower blood transfusions, infections, mortality, and length of stay compared to Surgical Cutdown.

Perclose patient outcomes:

Less likely to have an infection
Shorter hospital stay
Less likely to die within 30 days post-procedure
Less likely to require a blood transfusion


Early Ambulation and Discharge

For AF Ablation cases

Time management, patient and staff flow, hospital costs, and throughput can all impact overall hospital efficiency. Access site management, early ambulation and discharge with Perclose ProGlide™ Suture-Mediated Closure System can help reduce patient length of stay, optimize nursing time, improve patient flow, and drive overall hospital efficiency.

Early Ambulation and Same-Day Discharge for Atrial Fibrillation Ablation Cases

Dr. Sumit Verma from Baptist Heart and Vascular Institute discusses how the facility implemented same-day discharge for atrial fibrillation ablation cases and how the strategy has the potential to reduce complications, decrease resource utilization, and allow cost savings, while improving patient satisfaction.



Starclose SETM Vascular Closure System (VCS) 

The StarClose SE™ Vascular Closure System (VCS) can be utilised after arterial access procedures using 5-6F introducer sheaths and provides safe16, easy and extravascular percutaneous closure after diagnostic or interventional procedures. The system offers:


  • Rapid ambulation and haemostasis14
  • Extravascular closure with no intravascular footprint15
  • High technical procedure success rate* – a 100% success rate in CLIP14 and RISE16 studies for diagnostic patients
*Defined as attainment of final haemostasis using any method and freedom from major vascular complications

The secure, easy and extravascular solution for vascular closure
of 5-6F femoral artery access sites


  • Designed not to impact lumen diameter or distal blood flow
  • Proprietary nitinol design – nothing remains inside the artery
  • Re-access/Reclose


  • Advanced design for greater stability and ease of use
  • Numbered windows and numbered steps provide visual guidance for step completion15
  • Four clicks to close15

Gives In-Lab Confidence

  • 360º circumferential clip closure
  • Secure Closure – Close, Challenge and Confirm on the table gives you the close you can trust
  • Early ambulation – RISE Study median time to ambulation was 5.92 minutes (Per-Protocol Population RISE Study Endpoints)16


Starclose SETM Deployment



ProstarTM XL Percutaneous Vascular Surgical System (PVSS)

Percutaneous Vascular Surgical (PVS) System is designed for use in conjunction with 8.5-24F sheaths and uses two braided sutures to provide a secure closure for femoral arterial access sites.17 When compared to manual compression, Prostar XL™ PVS System reduces time to haemostasis and ambulation.*9

*The STAND II randomised trial evaluated the use of the 8Fr or 10Fr Prostar™ Plus device versus traditional compression in 515 patients undergoing diagnostic or interventional procedures. Median time to haemostasis (19 vs 243 minutes, p <.01) and time to ambulation (3.9 vs 14.8 hours, p <.01) were significantly shorter for Prostar™ group.1



Compression Assist Devices

FemoStopTM Gold Compression Assist Device

The FemoStopTM Compression Assist Device uses hands-free compression of the femoral artery or vein to offer precise haemostasis management and improved patient comfort compared to manual compression:

Offers Precise Placement and Control

  • Integrated manometer allows pressure to be adjusted based on patient status.
  • The inflatable, transparent dome offers precise pressure for effective hemostasis.
  • Adjustable belt designed to fit securely so small patient movements may not cause the device to slip.18

Improves Staff Efficiency and Safety19

  • Hands-free femoral artery or vein compression18 allows staff to monitor multiple patients at one time.
  • Transparent dome ensures puncture site visibility.
  • Hands-free compression minimises staff exposure to blood and reduces neck, arm, and wrist fatigue.


Watch FEMOSTOPTM GOLD step-by-step deployment

Discover Abbott’s Peripheral intervention technology


Abbott’s Peripheral Intervention Portfolio



1. Baim DS, et al. Am J Cardiol 2000. 85(7): 864-9.

2. Verma S EP Lab Digest 2020. 20(8): 33-37.

3. Verma S, et al., Feasibility and Safety of Same Day Discharge for Patients Undergoing Atrial Fibrillation (AF) Ablation in a Community Hospital Setting., in HRS. 2020.

4. Kar S, et al. JACC: Cardiovascular Interventions 2018. 11(4): S35-S35.

5. Schneider DB, Perclose ProGlide vs Surgical closure outcomes - Real world evidence in LINC. 2018: Finland.

6. Salcido R Adv Skin Wound Care 2017. 30(6): 246-247.

7. Abbott, Perclose™ ProGlide™ SMC System - Instructions for Use (IFU).

8. Abbott, Perclose™ ProStyle™ SCMR System - Instructions for Use (IFU).

9. Abbott, Testing data on file.

10. Bhatt DL, et al. Am J Cardiol 2002. 89(6): 777-9.

11. Mercandetti M and Cohem A. Wound Healing and Repair. Updated: 22/01/2021 Available at: [Accessed:21/09/2021].

12. Schneider DB, et al. J Comp Eff Res 2019. 8(16): 1381-1392.

13. Nelson PR, et al. J Vasc Surg 2014. 59(5): 1181-93.

14. Hermiller J, et al. J Invasive Cardiol 2005. 17(10): 504-10.

15. Abbott, StarClose SE™ VCS - Instructions for Use (IFU).

16. Burke MN, et al. Catheter Cardiovasc Interv 2012. 80(1): 45-52.

17. Abbott, Prostar XL™ Percutaneous Vascular Surgical System - Instructions for Use (IFU).

18. Abbott, Femostop™ Gold Compression Assist Device - Instructions for Use (IFU).

19. Sridhar K, et al. Cathet Cardiovasc Diagn 1996. 39(3): 224-9.


MAT-2117127 V2.0